ArticleNature communications2023
Microbially produced vitamin B12 contributes to the lipid-lowering effect of silymarin.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2024Trial
- Trial
- ROS/pH-Responsive Phenylboronic Acid-Chitosan Nanoparticles Improve Silymarin-Mediated Hepatoprotection After Hepatectomy With Gut-Liver Axis-Associated Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The gut-liver axis: microbial mechanisms and therapeutic implications in MAFLD.Frontiers in cellular and infection microbiology · 2026Review
- Dietary milk thistle meal supplementation modulates gut microbiota and improves performance and egg quality in late-phase laying hens.Frontiers in microbiology · 2026Article
- Article
- Vitamin B12 and Affective Disorders: A Focus on the Gut-Brain Axis.Alpha psychiatry · 2025Review
- The carotenoid torularhodin alleviates NAFLD by promoting Akkermanisa muniniphila-mediated adenosylcobalamin metabolism.Nature communications · 2025Article
- Advances in synthesizing plant-derived isoflavones and their precursors with multiple pharmacological activities using engineered yeasts.Microbial cell factories · 2025Review
- Comparative Analysis of Growth Dynamics and Relative Abundances of Gut Microbiota Influenced by Ketogenic Diet.Phenomics (Cham, Switzerland) · 2025Article
- Silibinin-derived microbiota enrich (R)-2,3-dihydroxy-isovalerate and ameliorate colitis via the GAT-3/RARβ/RORγt axis.The ISME journal · 2025Article
- The mechanism of Guanxin Qiwei dropping pills targetFrontiers in pharmacology · 2025Article
- Impact of the flavonoid-induced intestinal microbiota modulation on global energy metabolism: implication for obesity.Frontiers in nutrition · 2025Review
- Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Silybin A fromTheranostics · 2025Article
- Fermentative production of vitamin BFood science & nutrition · 2024Review
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome.mSystems · 2024Article
- Flavonoids and Their Role in Preventing the Development and Progression of MAFLD by Modifying the Microbiota.International journal of molecular sciences · 2024Review
- Effects of solid-state fermentation product of yeast supplementation on liver and intestinal health, and resistance of common carp (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Article
- Gut microbiota metabolite tyramine ameliorates high-fat diet-induced insulin resistance via increased CaThe EMBO journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silymarin has been used for improving hepatic damage and lipid disorders, but its action mechanism remains to be clarified. Here, we investigate the contributions of the gut microbiota to the improvement of liver lipid metabolism by silymarin. We find i) strong and significant microbial shifts upon silymarin but not silibinin treatment; ii) over 60% variations of liver fat are explained by silymarin-induced bacterial B12 production in male rats but not in male germ-free mice; iii) fecal microbiota transplantation confirms their protective roles against liver fat accumulation; iv) upregulation of one-carbon metabolism and fatty acid degradation pathways are observed based on the liver transcriptome analyses; and v) in humans the delta changes of serum B12 associate negatively with the fluctuations of serum triglycerides. Overall, we reveal a mechanism of action underpinning the lipid-lowering effect of silymarin via the gut microbiota and its vitamin B12 producing capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.